Cryotherapy in Dermatology: Uses and Outcomes

Cryotherapy is one of the most widely performed in-office dermatological procedures, used to destroy abnormal or unwanted tissue through controlled freezing. This page covers how the technique works at a cellular level, which skin conditions it addresses, how it compares to alternative treatments, and where clinical and regulatory boundaries apply. Understanding the scope and limitations of cryotherapy helps patients and clinicians frame realistic expectations for outcomes.

Definition and scope

Cryotherapy in dermatology refers to the therapeutic application of extreme cold — most commonly liquid nitrogen at approximately −196°C (−321°F) — to targeted skin lesions to induce controlled tissue destruction. The American Academy of Dermatology (AAD) recognizes cryotherapy as a standard-of-care procedure for a defined range of benign, premalignant, and select malignant skin conditions. It is categorized as a destructive modality, placing it alongside procedures such as electrodessication, curettage, and laser ablation, each with distinct depth-of-injury profiles.

Cryotherapy's scope within U.S. dermatology practice intersects the broader regulatory context for dermatology, including device oversight by the U.S. Food and Drug Administration (FDA). Liquid nitrogen delivery devices and cryotherapy spray units are classified under FDA's Center for Devices and Radiological Health (CDRH) as Class II medical devices requiring 510(k) clearance. The International Classification of Diseases, Tenth Revision (ICD-10), published by the World Health Organization (WHO), includes specific procedural codes for cryosurgery of skin lesions, facilitating insurance billing and outcome tracking across U.S. clinical systems.

How it works

Cryotherapy destroys tissue through two primary mechanisms: ice crystal formation within cells and vascular stasis. When liquid nitrogen contacts skin, the tissue temperature drops to between −25°C and −50°C within seconds — the threshold range at which irreversible cell death occurs in most epidermal and superficial dermal cells. This rapid freeze causes intracellular ice crystals to rupture cell membranes. During the subsequent thaw cycle, vascular damage produces ischemia that compounds cellular destruction.

The freeze-thaw cycle is the operative unit of cryotherapy. A single freeze-thaw cycle is standard for benign lesions; two cycles — separated by a controlled thaw interval of 30 to 60 seconds — are applied for actinic keratoses and certain premalignant lesions to increase depth of destruction. Each cycle extends penetration depth by approximately 1–2 mm, depending on application duration, spray distance, and skin thickness at the treatment site.

Three delivery methods are in common clinical use:

1. Cryospray — liquid nitrogen applied via a handheld unit with a precision nozzle; allows controlled surface area and duration; most common for actinic keratoses and flat warts
2. Cryoprobe — a metal-tipped applicator cooled by liquid nitrogen or nitrous oxide; used when contact pressure is preferable, such as for nodular lesions
3. Cotton-tipped applicator dipped in liquid nitrogen — a lower-cost, lower-precision method; tissue temperature achieved is less consistent, limiting use to superficial benign lesions

Depth of penetration is the key variable distinguishing these methods, as reviewed in clinical guidance published by the British Journal of Dermatology and the Journal of the American Academy of Dermatology.

Common scenarios

Cryotherapy is applied across a spectrum of diagnoses, from cosmetically bothersome benign growths to premalignant lesions requiring tissue clearance. The most frequently treated conditions fall into three categories:

Benign lesions:
- Common warts (verruca vulgaris) — caused by human papillomavirus (HPV); clearance rates at 3 months with liquid nitrogen cryotherapy range from 44% to 73% per systematic review data cited by the Cochrane Collaboration
- Seborrheic keratoses — treated for symptomatic or cosmetic indications
- Molluscum contagiosum, particularly in immunocompetent pediatric patients (see pediatric dermatology conditions)
- Dermatofibromas and lentigos

Premalignant lesions:
- Actinic keratoses (AK) — the primary indication in most U.S. practice settings; the AAD estimates that actinic keratoses affect more than 58 million Americans, and cryotherapy is endorsed as a first-line field therapy (AAD Clinical Practice Guideline, actinic keratosis)
- Bowen's disease (squamous cell carcinoma in situ)

Select low-risk malignancies:
- Superficial basal cell carcinoma — cryotherapy may be appropriate in non-facial locations for low-risk, well-demarcated lesions when surgical excision is contraindicated; Mohs surgery remains the preferred modality for high-risk facial or recurrent basal cell carcinoma

For skin cancer screening context and the lesion categories that inform cryotherapy candidacy, the skin cancer types and warning signs resource provides foundational classification detail.

Decision boundaries

Not every lesion is a cryotherapy candidate, and the decision involves clear clinical thresholds. Cryotherapy is contraindicated or requires modified technique in the following documented scenarios:

• Melanoma — cryotherapy is not appropriate for melanocytic lesions with malignant potential; tissue diagnosis via skin biopsy must precede any destructive treatment of pigmented lesions
• Cold urticaria or cryoglobulinemia — systemic hypersensitivity to cold represents a patient-level contraindication
• Lesions in high-risk anatomic sites — eyelid margins, nasal ala, and ears carry risk of cartilage necrosis with aggressive freeze times
• Patients with Raynaud's phenomenon or peripheral vascular disease — impaired vascular recovery increases risk of prolonged tissue necrosis

Compared to phototherapy for skin conditions, cryotherapy is a single-lesion or focal field intervention, not a whole-body or systemic treatment modality. Compared to topical medications such as imiquimod or 5-fluorouracil, cryotherapy achieves tissue destruction in a single visit rather than requiring multi-week adherence to a topical regimen — a practical factor in treatment selection for actinic keratosis.

The full spectrum of dermatological procedures and how cryotherapy fits within U.S. dermatology practice can be explored through the dermatology homepage, which covers the discipline's diagnostic and procedural landscape.

Post-procedure expectations include blistering within 24 hours, eschar formation, and re-epithelialization over 1 to 3 weeks depending on lesion size and anatomic location. Hypopigmentation is a recognized long-term risk, particularly in patients with darker skin tones, as discussed in clinical guidance addressing dermatology and skin of color.

References

• American Academy of Dermatology (AAD) — Clinical Practice Guidelines
• U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH) — 510(k) Premarket Notification Database
• World Health Organization — ICD-10 Online Browser
• Cochrane Collaboration — Interventions for Cutaneous Molluscum Contagiosum and Warts
• National Cancer Institute (NCI) — Skin Cancer Treatment (PDQ)
• British Journal of Dermatology — Published Clinical Practice Content

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)